Loading…
← CockpitCompetitor Analysis › 7447.T Nagaileben Co., Ltd.Open in the cockpit ↗

Nagaileben Co., Ltd.7447.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Distributors
Momentum neutral 52
Mkt cap
$319M
US dollars, full cap
Free float
61%
of shares outstanding
$/day
$1.11M
20-day average traded
Fwd P/E
18.2×
forward earnings
ROIC−WACC
+10.1 pp
WACC 5.0%
Hurdle
-12 pp
Req g minus delivered
Next earnings
29 days
17 Dec 2026
Close · JPY¥1,691
1D-1.3%
1W+1.0%
1M+0.6%
3M-6.2%
6M+0.3%
YTD-5.9%
1Y-3.6%
ATR %1.8%
52w lowhigh13.6% off high

What Nagaileben does

Employees: 487

Nagaileben at a glance

Size Nagaileben (7447.T) is a Japan Health Care company (Medical Distributors) with a market value of $319M, the 1320th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,691 on 18 Nov 2026.

Performance Over six months the shares gained 0.3%, against -5.6% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue grew 1.3% over the last twelve months (peer median +3.9%); the operating margin is 21.1% (peer median 1.9%).

Valuation It trades at 18.2× forward earnings against a peer median of 17.3× (5th cheapest of 9).

Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -12 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 10.1 points above its cost of capital (5.0% WACC).

Next results Next results expected around 17 Dec 2026 (exchange calendar; dates can move).

Relative performance

10011021 May 202621 Aug 202618 Nov 20267447.T 102Peer median 94
Six months, rebased to 100: Nagaileben against the median of its 20 peers (local-currency closes).

Nagaileben financials

Reported figures in JPY; fiscal year ends 2026-08-31. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue¥17.2B¥17.2B¥17.0B¥16.4B¥17.2B
Revenue growth—+1%+3%-4%—
Gross profit¥6.89B¥6.73B¥6.57B¥6.90B¥7.41B
EBITDA¥3.92B¥3.92B¥3.86B¥4.27B¥4.88B
Net income¥2.65B¥2.65B¥2.57B¥2.82B¥3.23B
Free cash flown/a¥3.31B¥1.89B¥2.14B¥1.55B
Capital expendituren/a¥335M¥389M¥168M¥284M
Total debt¥0¥0¥0¥0¥0

Quarterly statements and history in the cockpit →

Nagaileben competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%0%+20%3011660006683151410400007866176037166051363013706006282733688366ENTEROARJO-B603368DOCM74767447.T6-month return →1-month return →
Up and to the right = strong over both horizons. Nagaileben is the large dot.

Fundamentals: revenue growth against valuation

0%+20%20×40×3011662733NEU688366ENTEROARJO-B60336874767447.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Nagaileben is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%000668315141040000786051363013706006282733688366ENTERO6033683015847447.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Nagaileben is the large dot.

Nagaileben competitors and peer comparison

How Nagaileben compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nagaileben against its 20 peers (data as of 18 Nov 2026)
Measure7447.TPeer medianRank in peer set
1-month return+0.6%-4.1%6th highest of 21
6-month return+0.3%-5.6%8th highest of 21
Distance from 52-week high-13.6%-22.4%5th highest of 21
Revenue growth (TTM)+1.3%+3.9%7th lowest of 21
Operating margin21.1%1.9%highest of 21
Forward P/E18.2×17.3×5th cheapest of 9
Growth the price implies (Req g, 7 yrs)-12.7%4.7%least demanding of 16
Growth delivered (Del g)-0.4%+6.0%3rd lowest of 16
Hurdle (Req g minus delivered)-12.2 pp-5.0 pp4th least demanding of 16
ROIC minus cost of capital+10.1 pp-0.5 pphighest of 21
EV / EBITDA7.3×10.1×2nd cheapest of 4
Net debt / EBITDA-5.7×1.5×least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Nagaileben 7447.TJapan$319M0%+1%21%18.2×-12.7%-0.4%
Shanghai Universal Biotech 301166.SZChina$337M-15%+15%-4%25.3×n/an/a
Rongfeng 000668.SZChina$297M-32%+61%14%n/a9.6%+30.0%
Vital KSK 3151.TJapan$399M-1%+3%0%n/a4.7%+2.6%
Excelsior Medical 4104.TWTaiwan$404M+5%+11%8%n/a-1.2%+5.7%
Shenzhen Neptunus Bioengineering 000078.SZChina$411M-48%-22%-1%n/a58.3%-7.8%
Gongwin Biopharm 6617.TWOTaiwan$412M+87%+12%-530%n/an/an/a
Thalys Medical Technology 603716.SSChina$446M-33%-43%-18%n/an/an/a
Shanghai Lily & Beauty Cosmetics 605136.SSChina$449M-28%+5%2%n/a21.1%-18.1%
GKHT Medical Technology 301370.SZChina$525M-24%-11%1%n/a13.1%+7.5%
Shanghai New World 600628.SSChina$573M-10%-2%6%n/a-1.6%+1.0%
Arata 2733.TJapan$576M-3%+3%1%12.0×-6.2%+3.8%
Neuca NEU.WAPoland$795M-9%+8%2%15.3×5.3%+8.1%
Shanghai Haohai Biological Technology 688366.SSChina$878M-24%-9%-2%16.2×16.9%+13.2%
Entero Healthcare Solutions ENTERO.NSIndia$925M+60%+35%4%47.7×24.7%+29.9%
Arjo ARJO-B.STSweden$974M+42%0%8%21.1×-1.0%+3.9%
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%9.5×-9.7%+6.0%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%n/an/an/a
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%n/a-2.7%+17.9%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%n/an/an/a
AS ONE 7476.TJapan$1.10B+25%+10%12%18.4×0.0%+6.3%

Questions

Which companies are Nagaileben's closest peers?
The cockpit's peer set: Shanghai Universal Biotech (301166.SZ), Rongfeng (000668.SZ), Vital KSK (3151.T), Excelsior Medical (4104.TW), Shenzhen Neptunus Bioengineering (000078.SZ), Gongwin Biopharm (6617.TWO), Thalys Medical Technology (603716.SS), Shanghai Lily & Beauty Cosmetics (605136.SS).
Is Nagaileben expensive compared with its peers?
On forward p/e it trades at 18.2× against a peer median of 17.3×, 5th cheapest of 9 in its peer set. For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -12 pp: the price already allows for a slowdown.
How has Nagaileben stock performed?
Over six months to 18 Nov 2026 the shares returned +0.3% against -5.6% for the median peer; over one year -3.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.